European Commission approves Hulio (adalimumab biosimilar)for all indications of the reference drug.- Mylan + Fujifilm Kyowa Kirin Biologics.

The European commission (EC) has granted marketing authorization to Mylan and Fujifilm Kyowa Kirin Biologics for Hulio, a biosimilar to AbbVie�s Humira (adalimumab). The marketing authorization covers all indications for which Humira is approved, including inflammatory bowel disease (IBD). The authorization comes following a positive opinion adopted by the Committee for Medicinal Products.